Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Becton Dickinson and : BD - Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings

02/13/2020 | 07:05am EDT

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies.

The partnership reflects emerging health care trends toward faster, less expensive laboratory testing in customer-friendly health care settings with more convenient hours and locations, as well as rapid growth in the diagnostic testing market. The partnership builds on a collaboration between the two companies dating back to 2017. Its goal is to enable retail pharmacies to offer laboratory-quality diagnostic testing through Babson Diagnostics' service by combining BD's innovative capillary blood collection device in development with Babson Diagnostics' proprietary automated sample handling and analytical technologies, which are also in development.

BD's new capillary specimen collection device in development is designed to enable the collection of laboratory-quality specimens without the need to access a vein. Drawing from more than 70 years of specimen management success with BD Vacutainer devices, the small-volume blood collection devices being developed by BD will be designed for health care settings without a trained phlebotomist, such as retail pharmacies, physician offices, urgent care centers and skilled nursing facilities.

'BD has been a leader in blood collection technology with a long history of global innovation,' said Eric Olson, chief executive officer of Babson Diagnostics. 'The technology they are developing is critical to Babson's mission of making diagnostic blood testing more convenient and accessible without sacrificing accuracy or cost. Combining this technology with our own will allow us to bring diagnostic blood testing to retail pharmacies, making it easier for people to gain control over and improve their health.'

Babson Diagnostics' diagnostic blood testing model is designed to allow customers to get physician-ordered or self-ordered diagnostic blood tests at convenient retail pharmacies. In such a setting, customers can avoid long wait times and may benefit from longer hours of operation, low out-of-pocket costs, and a more pleasant blood collection experience.

'Patient expectations for health care are evolving, and patients are demanding care in more convenient settings. With our specimen management innovations, we hope to revolutionize diagnostic testing to meet patient expectations with laboratory-quality tests that can be performed with small blood samples that do not require venipuncture,' said Patrick Kaltenbach, executive vice president and president, life sciences at BD. 'Babson Diagnostics will help bring BD's advanced capillary blood collection products to emerging health care settings, making laboratory-quality diagnostics more accessible to patients in the U.S. and around the world.'

Babson Diagnostics and BD are undertaking clinical studies on these devices in retail pharmacy settings. BD plans to prepare regulatory submissions to the U.S. Food and Drug Administration and other global regulatory bodies upon completion of these clinical studies.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

About Babson Diagnostics

Babson Diagnostics aims to bring diagnostic blood testing to the retail pharmacy counter, making it easier, faster, and more pleasant for customers to routinely monitor and improve their health. Babson's proprietary technological ecosystem is designed to deliver accurate diagnostic results with a more human experience. Based in Austin, Texas, its vision for diagnostic blood testing-built on accuracy, convenience, and accessibility-combines transformative diagnostic technology with a customer-first, retail-centric business model that aims to improve customer health and experience.

Contact:

Tel: 512.917.4319

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about BECTON, DICKINSON AND COMPANY
06/18Correction to Becton Dickinson Outlook Article on Feb. 6, 2020
DJ
06/14TELEPHARMA DISCONNECT : Federal Circuit Reverses PTAB On Obviousness
AQ
06/14BECTON DICKINSON ANDá : USA Swimming Partners with BD to Provide COVID-19 Screen..
AQ
06/11BECTON DICKINSON ANDá : USA Swimming Partners with BD to Provide COVID-19 Screen..
PR
06/08INOGENá : Appoints Becton Dickinson Executive Stanislav Glezer as Chief Medical ..
MT
06/08BECTON DICKINSON ANDá : Reaches Injection Device Milestone in Support of Global ..
MT
06/08BECTON DICKINSON ANDá : BD Hits 2 Billion Injection Device Milestone in Support ..
PR
06/08BECTON, DICKINSON AND COMPANY : Ex-dividend day for
FA
06/02INSIDER TRENDS : Selling By Insiders Lingers at Becton Dickinson
MT
06/02BECTON DICKINSON ANDá : BD Advances Leadership in Cybersecurity Preparedness, Tr..
PR
More news
Financials (USD)
Sales 2021 19 455 M - -
Net income 2021 2 308 M - -
Net Debt 2021 13 630 M - -
P/E ratio 2021 30,0x
Yield 2021 1,54%
Capitalization 69 953 M 69 953 M -
EV / Sales 2021 4,30x
EV / Sales 2022 4,24x
Nbr of Employees 72 000
Free-Float 79,2%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 279,80 $
Last Close Price 240,54 $
Spread / Highest target 24,7%
Spread / Average Target 16,3%
Spread / Lowest Target 8,09%
EPS Revisions
Managers and Directors
NameTitle
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher R. Reidy Chief Financial & Administrative Officer, EVP
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BECTON, DICKINSON AND COMPANY-3.87%69 953
ABBOTT LABORATORIES0.77%196 037
MEDTRONIC PLC5.20%165 794
HOYA CORPORATION1.26%48 451
ALIGN TECHNOLOGY, INC.12.59%47 612
SARTORIUS STEDIM BIOTECH S.A.30.77%41 615